Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672523 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| SCHEMBL1382764 | 0.79 | SMN1; SMN2 (0.95) | SMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL5222020 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| SCHEMBL5813832 | 0.78 | SMN1; SMN2 (0.98) | SMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL13403410 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| SCHEMBL763452 | 0.76 | HTT (0.78) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| Eprobemide SCHEMBL570896 | 0.76 | ALDH1A1 (0.85) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| SCHEMBL12459935 | 0.76 | CD274 (0.79) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| SCHEMBL3034681 | 0.76 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 | |
| SCHEMBL2249600 | 0.75 | TSHR (0.74) | SMN1; SMN2ALDH1A1TSHRKDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795290-B2 | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7410988-B2 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | SQUARE 1 BANK | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | ATP5ME, ATP5MG, ATP5MK | SMN1; SMN2 4020/4885ALDH1A1 554/4885TSHR 2723/4885 |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | SMN1; SMN2 4020/4885ALDH1A1 554/4885TSHR 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.